The same synergy is found between MYC-driven neuroblastoma and Augα overexpression, suggesting that inhibitory antibodies might be effective for patient subgroups with ligand misregulation in addition to the potential benefits of ALK TKI treatment [47]. This evidence concerns the gene ALKAL2 and neuroblastoma.